Use este identificador para citar ou linkar para este item: http://repositorio.bc.ufg.br/handle/ri/16719
Registro completo de metadados
Campo DCValorIdioma
dc.creatorToscano, Cristiana Maria-
dc.creatorXiaohui, Zhuo-
dc.creatorImai, Kumiko-
dc.creatorDuncan, Bruce Bartholow-
dc.creatorPolanczyk, Carísi Anne-
dc.creatorPing, Zhang-
dc.creatorEngelgau, Michael-
dc.creatorSchmidt, Maria Inês-
dc.date.accessioned2019-01-14T13:30:57Z-
dc.date.available2019-01-14T13:30:57Z-
dc.date.issued2015-
dc.identifier.citationTOSCANO, Cristiana M. et al. Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience. Diabetology & Metabolic Syndrome, London, v. 7, n. 95, 2015.pt_BR
dc.identifier.issne- 1758-5996-
dc.identifier.urihttp://repositorio.bc.ufg.br/handle/ri/16719-
dc.description.abstractBackground: The cost-effectiveness of screening for type 2 diabetes mellitus (DM2) in developing countries remains unknown. The Brazilian government conducted a nationwide population screening program for type 2 diabetes mellitus (BNDSP) in which 22 million capillary glucose tests were performed in individuals aged 40 years and older. The objective of this study was to evaluate the life-time cost-effectiveness of a national population-based screening program for DM2 conducted in Brazil. Methods: We used a Markov-based cost-effectiveness model to simulate the long-term costs and benefits of screening for DM2, compared to no screening program. The analysis was conducted from a public health care system perspective. Sensitivity analyses were conducted to examine the robustness of results to key model parameters. Results: Brazilian National diabetes screening program will yield a large health benefit and higher costs. Compared with no screening, screen detection of undiagnosed diabetes resulted in US$ 31,147 per QALY gained. Results from sensitivity analyses found that screening targeted at hypertensive individuals would cost US$ 22,695/QALY. When benefits from early glycemic control on cardiovascular outcomes were considered, the cost per QALY gained would reduce significantly. Conclusions: In the base case analysis, not considering the intangible benefit of transferring diabetes management to primary care nor the benefit of using statin to treat eligible diabetic patients, CE ratios were not cost-effective con-sidering thresholds proposed by the World Health Organization. However, significant uncertainty was demonstrated in sensitivity analysis. Our results indicate that policy-makers should carefully balance the benefit and cost of the program while considering using a population-based approach to screen for diabetes.pt_BR
dc.language.isoengpt_BR
dc.rightsAcesso Abertopt_BR
dc.titleCost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experiencept_BR
dc.typeArtigopt_BR
dc.publisher.countryGra-bretanhapt_BR
dc.identifier.doi10.1186/s13098-015-0090-8-
dc.publisher.departmentInstituto de Patologia Tropical e Saúde Pública - IPTSP (RG)pt_BR
Aparece nas coleções:IPTSP - Artigos publicados em periódicos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Artigo - Cristiana Maria Toscano - 2015.pdf1,12 MBAdobe PDFThumbnail
Baixar/Abrir


Este item está licenciada sob uma Licença Creative Commons Creative Commons